Single-Stranded Nucleic Acid Molecule for Controlling Gene Expression
Abstract
Provided is a novel nucleic acid molecule that is a single-stranded nucleic acid molecule including an expression inhibitory sequence that inhibits expression of a target gene. The single-stranded nucleic acid molecule includes, in sequence from the 5′ side to the 3′ side: a 5′ side region (Xc); an inner region (Z); and a 3′ side region (Yc). The inner region (Z) is composed of an inner 5′ side region (X) and an inner 3′ side region (Y) that are linked to each other. The 5′ side region (Xc) is complementary to the inner 5′ side region (X). The 3′ side region (Yc) is complementary to the inner 3′ side region (Y). At least one of the inner region (Z), the 5′ side region (Xc), and the 3′ side region (Yc) includes the expression inhibitory sequence.
Claims
exact text as granted — not AI-modified1 . A single-stranded nucleic acid molecule comprising:
an expression inhibitory sequence that inhibits expression of a target gene, wherein the single-stranded nucleic acid molecule comprises, in sequence from a 5′ side to a 3′ side: a 5′ side region (Xc); an inner region (Z); and a 3′ side region (Yc), the inner region (Z) is composed of an inner 5′ side region (X) and an inner 3′ side region (Y) that are linked to each other, the 5′ side region (Xc) is complementary to the inner 5′ side region (X), the 3′ side region (Yc) is complementary to the inner 3′ side region (Y), and at least one of the inner region (Z), the 5′ side region (Xc), and the 3′ side region (Yc) comprises the expression inhibitory sequence.
2 . The single-stranded nucleic acid molecule according to claim 1 , further comprising:
a linker region (Lx) between the 5′ side region (Xc) and the inner 5′ side region (X), wherein the 5′ side region (Xc) and the inner 5′ side region (X) are linked to each other via the linker region (Lx).
3 . The single-stranded nucleic acid molecule according to claim 1 , further comprising:
a linker region (Ly) between the 3′ side region (Yc) and the inner 3′ side region (Y), wherein the 3′ side region (Yc) and the inner 3′ side region (Y) are linked to each other via the linker region (Ly).
4 . The single-stranded nucleic acid molecule according to claim 1 , further comprising:
a linker region (Lx) between the 5′ side region (Xc) and the inner 5′ side region (X); and a linker region (Ly) between the 3′ side region (Yc) and the inner 3′ side region (Y), wherein the 5′ side region (Xc) and the inner 5′ side region (X) are linked to each other via the linker region (Lx), and the 3′ side region (Yc) and the inner 3′ side region (Y) are linked to each other via the linker region (Ly).
5 . The single-stranded nucleic acid molecule according to claim 1 , wherein the number of bases (Z) in the inner region (Z), the number of bases (X) in the inner 5′ side region (X), the number of bases (Y) in the inner 3′ side region (Y), the number of bases (Xc) in the 5′ side region (Xc), and the number of bases (Yc) in the 3′ side region (Yc) satisfy conditions of Expressions (1) and (2):
Z=X+Y (1)
Z≧Xc+Yc (2)
6 . The single-stranded nucleic acid molecule according to claim 1 , wherein the number of bases (X) in the inner 5′ side region (X), the number of bases (Xc) in the 5′ side region (Xc), the number of bases (Y) in the inner 3′ side region (Y), and the number of bases (Yc) in the 3′ side region (Yc) satisfy any of conditions (a) to (d):
(a) Conditions of Expressions (3) and (4) are satisfied;
X>Xc (3)
Y=Yc (4)
(b) Conditions of Expressions (5) and (6) are satisfied;
X=Xc (5)
Y>Yc (6)
(c) Conditions of Expressions (7) and (8) are satisfied;
X>Xc (7)
Y>Yc (8)
(d) Conditions of Expressions (9) and (10) are satisfied;
X=Xc (9)
Y=Yc (10).
7 . The single-stranded nucleic acid molecule according to claim 6 , wherein, in the conditions (a) to (d), the difference between the number of bases (X) in the inner 5′ side region (x) and the number of bases (Xc) in the 5′ side region (Xc), and the difference between the number of bases (Y) in the inner 3′ side region (Y) and the number of bases (Yc) in the 3′ side region (Yc) satisfy the following conditions:
(a) Conditions of Expressions (11) and (12) are satisfied;
X−Xc= 1,2 or 3 (11)
Y−Yc= 0 (12)
(b) Conditions of Expressions (13) and (14) are satisfied;
X−Xc= 0 (13)
Y−Yc= 1,2 or 3 (14)
(c) Conditions of Expressions (15) and (16) are satisfied;
X−Xc= 1,2 or 3 (15)
Y−Yc= 1,2 or 3 (16)
(d) Conditions of Expressions (17) and (18) are satisfied;
X−Xc= 0 (17)
Y−Yc= 0 (18).
8 . The single-stranded nucleic acid molecule according to claim 1 , wherein the number of bases (Z) in the inner region (Z) is 19 or more.
9 . The single-stranded nucleic acid molecule according to claim 8 , wherein the number of bases (Z) in the inner region (Z) is 19 to 30.
10 . The single-stranded nucleic acid molecule according to claim 1 , wherein the number of bases (Xc) in the 5′ side region (Xc) is 1 to 11.
11 . The single-stranded nucleic acid molecule according to claim 10 , wherein the number of bases (Xc) in the 5′ side region (Xc) is 1 to 7.
12 . The single-stranded nucleic acid molecule according to claim 10 , wherein the number of bases (Xc) in the 5′ side region (Xc) is 1 to 3.
13 . The single-stranded nucleic acid molecule according to claim 1 , wherein the number of bases (Yc) in the 3′ side region (Yc) 1 to 11.
14 . The single-stranded nucleic acid molecule according to claim 13 , wherein the number of bases (Yc) in the 3′ side region (Yc) is 1 to 7.
15 . The single-stranded nucleic acid molecule according to claim 13 , wherein the number of bases (Yc) in the 3′ side region (Yc) is 1 to 3.
16 . The single-stranded nucleic acid molecule according to claim 1 , wherein the single-stranded nucleic acid molecule comprises at least one modified residue.
17 . The single-stranded nucleic acid molecule according to claim 1 , further comprising a labeling substance.
18 . The single-stranded nucleic acid molecule according to claim 1 , further comprising a stable isotope.
19 . The single-stranded nucleic acid molecule according to claim 1 , which is an RNA molecule.
20 . The single-stranded nucleic acid molecule according to claim 2 , wherein the linker region (Lx) and/or the linker region (Ly) is composed of at least one of a nucleotide residue and a non-nucleotide residue.
21 . The single-stranded nucleic acid molecule according to claim 20 , wherein the nucleotide residue is an unmodified nucleotide residue and/or a modified nucleotide residue.
22 . The single-stranded nucleic acid molecule according to claim 20 , wherein the linker region (Lx) and/or the linker region (Ly) is composed of any of residues (1) to (7):
(1) an unmodified nucleotide residue (2) a modified nucleotide residue (3) an unmodified nucleotide residue and a modified nucleotide residue (4) a non-nucleotide residue (5) a non-nucleotide residue and an unmodified nucleotide residue (6) a non-nucleotide residue and a modified nucleotide residue (7) a non-nucleotide residue, an unmodified nucleotide residue, and a modified nucleotide residue.
23 . The single-stranded nucleic acid molecule according to claim 1 , wherein the total number of bases in the single-stranded nucleic acid molecule is 50 or more.
24 . The single-stranded nucleic acid molecule according to claim 1 , wherein expression of the gene is inhibited by RNA interference.
25 . The single-stranded nucleic acid molecule according to claim 1 , wherein a base sequence of the single-stranded nucleic acid molecule is any of SEQ ID NOs: 2, 7, 8, 13, 14, 29 to 35, 37, 43, 44, 47, 48, and 51 to 80.
26 . (canceled)
27 . A pharmaceutical composition comprising: the single-stranded nucleic acid molecule according to claim 1 .
28 . A method of treating inflammation in a subject comprising
administering the pharmaceutical composition according to claim 27 to the subject.
29 . A method of inhibiting expression of a target gene, the method comprising the step of: using the single-stranded nucleic acid molecule according to claim 1 .
30 . The method according to claim 29 , comprising the step of: administering the single-stranded nucleic acid molecule to a cell, a tissue, or an organ.
31 . The method according to claim 30 , wherein the single-stranded nucleic acid molecule is administered in vivo or in vitro.
32 . The method according to claim 29 , wherein expression of the gene is inhibited by RNA interference.
33 . A method of inducing RNA interference that inhibits expression of a target gene, the method comprising the step of: using the single-stranded nucleic acid molecule according to claim 1 .
34 . A method of treating a disease, the method comprising the step of:
administering the single-stranded nucleic acid molecule according to claim 1 , to a patient, wherein the single-stranded nucleic acid molecule comprises, as the expression inhibitory sequence, a sequence that inhibits expression of a gene causing the disease.
35 - 36 . (canceled)
37 . A nucleic acid molecule for use in treatment of a disease, wherein
the nucleic acid molecule is the single-stranded nucleic acid molecule according to claim 1 , and the single-stranded nucleic acid molecule comprises, as the expression inhibitory sequence, a sequence that inhibits expression of a gene causing the disease.Join the waitlist — get patent alerts
Track US2015011605A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.